206 related articles for article (PubMed ID: 26549039)
1. Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Kurakula M; Ahmed TA
Curr Drug Deliv; 2016; 13(2):211-20. PubMed ID: 26549039
[TBL] [Abstract][Full Text] [Related]
2. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.
Ahmed TA; Alharby YA; El-Helw AR; Hosny KM; El-Say KM
Drug Des Devel Ther; 2016; 10():405-15. PubMed ID: 26855565
[TBL] [Abstract][Full Text] [Related]
3. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.
Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2017; 12():1863-1875. PubMed ID: 28331311
[TBL] [Abstract][Full Text] [Related]
4. Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium.
Arafa MG; Girgis GNS; El-Dahan MS
Int J Nanomedicine; 2020; 15():1335-1347. PubMed ID: 32184589
[TBL] [Abstract][Full Text] [Related]
5. Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer.
Ray S; Ghosh Ray S; Mandal S
Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):944-954. PubMed ID: 27327352
[TBL] [Abstract][Full Text] [Related]
6. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
Salama AH; Mahmoud AA; Kamel R
AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
[TBL] [Abstract][Full Text] [Related]
7. Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.
Kurakula M; El-Helw AM; Sobahi TR; Abdelaal MY
Int J Nanomedicine; 2015; 10():321-34. PubMed ID: 25609947
[TBL] [Abstract][Full Text] [Related]
8. Imaging the porous structure in the core of degrading PLGA microparticles: The effect of molecular weight.
Mylonaki I; Allémann E; Delie F; Jordan O
J Control Release; 2018 Sep; 286():231-239. PubMed ID: 30071251
[TBL] [Abstract][Full Text] [Related]
9. Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia.
Mathur M; Devi Vemula K
Drug Dev Ind Pharm; 2018 Dec; 44(12):2048-2060. PubMed ID: 30073852
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-Coated Poly(lactic-co-glycolic acid)-Diiodinated boron-Dipyrromethene Nanoparticles Improve Tumor Selectivity and Stealth Properties in Photodynamic Cancer Therapy.
Voon SH; Tiew SX; Kue CS; Lee HB; Kiew LV; Misran M; Kamkaew A; Burgess K; Chung LY
J Biomed Nanotechnol; 2016 Jul; 12(7):1431-52. PubMed ID: 29336539
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
Zhang D; Kong YY; Sun JH; Huo SJ; Zhou M; Gui YL; Mu X; Chen H; Yu SQ; Xu Q
Int J Nanomedicine; 2017; 12():2081-2108. PubMed ID: 28356731
[TBL] [Abstract][Full Text] [Related]
12. Enhanced encapsulation and bioavailability of breviscapine in PLGA microparticles by nanocrystal and water-soluble polymer template techniques.
Wang H; Zhang G; Ma X; Liu Y; Feng J; Park K; Wang W
Eur J Pharm Biopharm; 2017 Jun; 115():177-185. PubMed ID: 28263795
[TBL] [Abstract][Full Text] [Related]
13. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
14. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir.
Yang X; Shah SJ; Wang Z; Agrahari V; Pal D; Mitra AK
Drug Deliv; 2016 Sep; 23(7):2399-2409. PubMed ID: 25564964
[TBL] [Abstract][Full Text] [Related]
16. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
Rahman Z; Zidan AS; Habib MJ; Khan MA
Int J Pharm; 2010 Apr; 389(1-2):186-94. PubMed ID: 20038446
[TBL] [Abstract][Full Text] [Related]
17. An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats.
Ahmed TA; Mussari MA; Abdel-Hady SE; El-Say KM
Drug Des Devel Ther; 2019; 13():4035-4051. PubMed ID: 31839704
[TBL] [Abstract][Full Text] [Related]
18. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
19. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine.
Grabovac V; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2007 Jul; 33(7):767-74. PubMed ID: 17654025
[TBL] [Abstract][Full Text] [Related]
20. Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting.
Pandey S; Vijayendra Swamy SM; Ubaid Ulla UM; Gupta A; Patel H; Yadav JS
Curr Drug Deliv; 2017 Sep; 14(6):887-899. PubMed ID: 27538461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
